AG真人官方

Form 4 filing for 8x8, Inc. (EGHT) discloses that independent director Alison Gleeson received an equity grant on 07/25/2025.

• Grant details: 66,502 restricted stock units (RSUs) awarded at no cost. RSUs vest in full on the earlier of 25 Jul 2026 or the next annual shareholder meeting, contingent on continued board service.
• Post-grant ownership: Gleeson now beneficially owns 230,597 EGHT common shares, held directly.
• Purpose: Routine annual director compensation; no open-market purchase or sale took place.

No derivative securities were reported. The transaction does not affect share count, cash flow, or earnings but modestly increases insider ownership, potentially aligning director incentives with shareholder interests.

Okta CEO Todd McKinnon filed a Form 4 disclosing multiple transactions on 21 Jul 2025:

• Option exercises (Code M): 5,438 Class A shares at $39.21 and 47,000 Class B shares at $8.97 were converted to Class A. All options were fully vested.
• Open-market sales (Code S): 11,482 shares at a weighted-average $94.98 and 20,110 shares at $95.48, for total gross proceeds of roughly $3.0 million.
• Gift/transfer (Code G): 47,000 Class B shares were moved to a trust, which now holds 6,366,778 Class A-equivalent shares.

After the transactions, McKinnon鈥檚 direct ownership fell from 52,274 to 20,682 Class A shares, while indirect ownership via trust remains substantial at 6.37 million shares. The share sales represent <0.5 % of his combined holdings and were executed under a pre-arranged Rule 10b5-1 plan adopted 15 Apr 2024.

No earnings or company guidance were included; the filing strictly documents insider trading activity.

Solarius Capital Sponsor, LLC has filed an initial Form 3 disclosing its position in Solarius Capital Acquisition Corp. (SOCA) following the SPAC鈥檚 15 Jul 2025 IPO event. The sponsor directly owns 5,750,000 Class B founder shares; these convert 1-for-1 into Class A ordinary shares in connection with a future business combination and carry no expiration. Up to 750,000 shares are subject to forfeiture if the underwriters do not fully exercise their over-allotment option, as outlined in the S-1 prospectus (File No. 333-288078). The sponsor is classified as a director by deputization and a >10% beneficial owner. Although three individuals (David Saab, Charles Ecalle, Evangelia Kallitsi) manage the sponsor, none is deemed to have separate voting or dispositive control. No additional derivative securities are reported. The filing is a routine ownership disclosure that does not modify the capital structure or provide operating results.

Item 5.02 8-K: On 18 Jul 2025 Lixte Biotechnology appointed Jason Sawyer and Dr. Michael Holloway as independent directors under designation rights granted to investors that bought 3,573,190 Series B Preferred Shares on 3 Jul 2025. Sawyer also becomes Chair of the Compensation Committee and joins the Audit Committee.

To accommodate the appointments, Dr. Stephen Forman and Dr. Yun Yen resigned from the Board and moved to the company鈥檚 Scientific Advisory Committee. The company states these departures were not due to disagreements.

Separately, Chief Medical Officer Dr. Jan Schellens tendered his resignation and his consulting agreement will end 31 Jul 2025 so he can pursue other opportunities; no disputes were cited.

No financial results, guidance, or operational metrics were provided鈥攖his filing is strictly a corporate-governance update linked to the recent preferred-equity financing.

Okta, Inc. (NYSE: OKTA) filed a Form 144 disclosing an intended sale of 12,000 common shares by insider Jonathan James Addison. The shares have an aggregate market value of approximately $1.10 million based on the price at the time of filing, and will be executed through Morgan Stanley Smith Barney LLC on or about 15 July 2025. The shares represent roughly 0.007 % of the 167.16 million shares outstanding, indicating a small, non-dilutive transaction.

The filing also reports that Addison, under a Rule 10b5-1 trading plan, sold 6,027 shares on 14 July 2025 for $554,523.18. The securities to be sold were acquired as restricted stock units (RSUs) on 15 Dec 2023. No details were provided about any material consideration other than the equity award itself.

Form 144s are advance notices and do not guarantee that the sale will occur, but they do signal insider intent. Given the modest size relative to Okta鈥檚 float and the existence of a pre-arranged 10b5-1 plan, the market impact is expected to be limited. Investors commonly monitor such filings for sentiment cues; however, the data here suggest an orderly diversification rather than a strategic shift.

Electronic Arts Inc. (EA) filed a Form 144 indicating that insider Jacob J. Schatz intends to sell 1,500 common shares through Morgan Stanley Smith Barney on or about 15 July 2025. The shares carry an aggregate market value of $223,245 based on the filing's reference price and represent only 0.0006 % of EA鈥檚 250,765,972 shares outstanding. The securities were originally acquired via RSU/PSU awards on 17 May 2012.

The same insider has already disposed of 3,000 shares in two Rule 10b5-1 transactions during the past three months (15 May 2025 and 16 June 2025) for combined gross proceeds of roughly $447,497. Assuming the proposed sale is executed, total insider disposals within the rolling 90-day window will reach 4,500 shares valued at about $670,742.

While the dollar amount is notable, the volume is de minimis relative to EA鈥檚 float and does not, by itself, signal a material shift in fundamentals. However, investors often monitor sustained insider selling for sentiment clues, especially when clustered within short periods.